Five Prime Therapeutics 3Q16 Earnings Update November 2016

Five Prime Therapeutics presented its third quarter 2016 earnings update, highlighting progress in its oncology-focused pipeline with multiple clinical candidates including Cabiralizumab (FPA008), FPA144, and FP-1039. The company provided forward-looking guidance on clinical trial timelines, cash position, and operational metrics for full-year 2016.